Events

Liberyx Therapeutics Completes Series A Fundraising

May 06, 2022, 06:42 GMT

With multiple promising candidates for rare neurometabolic disorders, Liberyx Therapeutics is at the forefront of developing safe and efficacious therapies for our patients.

Events

Events

Liberyx Therapeutics Completes Series A Fundraising

ALEX YANG J.D., L.L.M. – Chief Executive Officer

Mitchel S. Berger, M.D., F.A.C.S., F.A.A.N.S.

Luis A Rojas, Ph.D. – Head of Clinical Development, Statistical Analysis and Technologies

Hahn-Jun Lee, Ph.D., Chief Science Officer

Dr. Hynda K. Kleinman, Ph.D.

Colleen Johnson, M.S., D.A.B.T. – Head of Toxicology

Dr. David R. Luke, BSc.Pharm., PharmD., FACA, FCCP – Chief Medical Officer

Dr. Scott Baraban, Ph.D.

Jay Vijayan, Ph.D.

Dr. Theron (Ted) Odlaug, Ph.D.

Dr. Kalipada Pahan, Ph.D.

Mary Shatzoff, M.S., Head of Regulatory Affairs

Anthony Lam – Chief Financial Officer